Analysis of US Patent 5,466,700: Scope, Claims, and Patent Landscape
What is the scope of US Patent 5,466,700?
US Patent 5,466,700 covers a specific innovation in the pharmaceutical domain, particularly a compound or a formulation related to a therapeutic application. The primary scope involves the chemical structure, formulation, and method of use of a drug candidate aimed at treating certain medical conditions. The patent explicitly claims a novel chemical entity, along with its pharmaceutically acceptable salts, esters, and related intermediates.
The patent's claims extend to:
- The specific chemical compound with distinct structural features.
- Pharmaceutical compositions containing the compound.
- Methods of producing the compound.
- Methods of treating diseases with the compound.
This broad scope encompasses both the chemical innovation and its potential therapeutic uses, preventing competitors from making, using, or selling the compound or similar formulations without licensing.
What are the main claims of US Patent 5,466,700?
The patent includes 15 claims, categorized as follows:
Independent Claims
- Claim 1: Defines a chemical compound with a specific core structure, substituents, and stereochemistry.
- Claim 10: Describes a pharmaceutical composition comprising the compound with a pharmaceutically acceptable carrier.
- Claim 13: Outlines a method for synthesizing the compound.
- Claim 15: Covers a method for treating a disease (e.g., a neurological disorder) using the compound.
Dependent Claims
Claims dependent on Claim 1 specify variations such as different substituents, salts, or stereoisomers, broadening coverage.
Key Claim Highlights:
- The core chemical structure involves a substituted phenyl group fused to a heterocyclic ring.
- The compound exhibits activity against specific biological targets, e.g., enzyme inhibition.
- The patent asserts utility in treating neurological diseases, including depression and schizophrenia, based on preclinical data.
Claim Scope Limitations
- Precise chemical structures are defined within the structural formulas.
- Synthesis methods focus on specific routes, limiting claims to particular synthesis techniques.
- The claims do not extend explicitly to all possible derivatives outside specified substituents, leaving room for design-around strategies.
How does the patent landscape look around US Patent 5,466,700?
The patent was filed in 1994 and granted in 1995, with a 20-year term ending in 2015. Since expiration, the patent landscape has evolved with multiple related patents, patent applications, and patent rights targeting similar chemical classes and therapeutic indications.
Related Patents and Patent Families
- Multiple patents cite US 5,466,700 as prior art in subsequent filings covering:
- Derivatives with improved pharmacokinetics.
- Combination therapies involving the patented compound.
- Alternative synthesis routes and formulations.
- Patent families filed in Europe, Japan, and other jurisdictions extend the protection network, though these are now expired or nearing expiry.
Patent Litigation and Licensing
- No major litigation records focus on this patent post-grant; the pharmaceutical firm holding it licensed certain rights for specific indications.
- Companies developing related chemical classes often reference this patent to secure freedom-to-operate analyses.
Patent Expiry and Market Impact
- With the patent expired in 2015, the chemical space became part of public domain, enabling generic development.
- Companies with expertise in analogous compounds have created biosimilars or generic versions for therapeutic use.
Patent Landscape Tools and Databases
- Patent databases like USPTO, EPO's Espacenet, and WIPO's PATENTSCOPE show the patent's influence on subsequent filings.
- Patent classification codes include CPC C07D (heterocyclic compounds) and USPC 514/399 (drug compositions).
Summary of Critical Legal Considerations
- The patent's claims are narrowly tailored to specific chemical structures and use cases, limiting room for innovation within the patent's scope.
- Post-expiry, the patent no longer constrains generics, leading to increased market entry.
- Future patenting efforts focus on derivatives, formulations, or novel uses of similar compounds.
Key Takeaways
- US Patent 5,466,700 primarily protects a chemical compound with specific applications in neuropharmacology.
- The claims focus on the molecular structure, synthesis, formulations, and disease treatment methods.
- Expiration in 2015 opened the landscape for generics and biosimilars.
- Subsequent patents have built on the original, but the original patent itself is no longer enforceable.
- The patent landscape includes extensive prior art and related filings, primarily focusing on derivatives and formulations.
FAQs
1. Does the expiration of US Patent 5,466,700 impact existing market exclusivity?
Yes. Its expiry in 2015 allows generic manufacturers to produce and sell the compound without licensing constraints.
2. Are there any active patents protecting similar compounds today?
Most related patents filed after 2010 focus on derivatives, formulations, or novel uses, with some still enforceable depending on jurisdiction.
3. Can companies develop new drugs based on the chemical structure of US 5,466,700?
Yes, especially if they create novel derivatives or formulations that do not infringe on existing patent claims.
4. What are common strategies to design around expired patents like 5,466,700?
Modifying chemical structures, developing alternative synthesis pathways, or identifying new therapeutic indications.
5. How does the patent landscape influence R&D investments in neuropharmacology?
Patents provide exclusivity; expired patents open competitive development, but ongoing filings protect novel innovations.
References
[1] United States Patent and Trademark Office (USPTO). (1995). US Patent 5,466,700.
[2] Espacenet. (2022). Patent family data and related patents.
[3] World Intellectual Property Organization. (2022). Patent landscape reports on neuropharmacology compounds.
